MAPK9
Mitogen-activated protein kinase 9
As of the edition of 20 October 2026, MAPK9 (mitogen-activated protein kinase 9, UniProt P45984) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P45984
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 5
- Disease areas
- Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 3
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tanzisertib | Stopped | Phase 2 | none listed |
| Bentamapimod | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| PregLem | Route A |
The other 0 companies at MAPK9
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at MAPK9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.